Silence Therapeutics (NASDAQ: SLN) Announced the Closing of Its Upsized $201.3 Million Underwritten Public Offering of American Depositary Shares Priced August 11 at $13.50 per ADS for 12,962,963 ADSs, With Underwriters (Jefferies, Morgan Stanley, Cantor Fitzgerald, and William Blair as Joint Book-Running Managers) Fully Exercising Their 30-Day Option to Purchase an Additional 1,944,444 ADSs Bringing Total to 14,907,407 ADSs; The Financing Follows the August 10 Phase 2 SANRECO Trial Win in Polycythemia Vera With Divesiran (First-in-Class TMPRSS6-Targeting siRNA) Achieving an 88% Response Rate Versus 19% on Placebo (P<0.0001, 69% Placebo-Adjusted Response Rate); Capital Advances Divesiran Into Phase 3 (Planned H1 2027) Plus Broader Hepatic-Target GalNAc-Conjugated siRNA Portfolio Progression
Silence Therapeutics (NASDAQ: SLN) announced the closing of its upsized $201.3 million underwritten public offering of American Depositary Shares. Terms: priced August 11 at $13.50 per ADS for 12,962,963 ADSs. The underwriters (Jefferies, Morgan Stanley, Cantor Fitzgerald, and William Blair as joint book-running managers) fully exercised their 30-day option to purchase an additional 1,944,444 ADSs, bringing the total offering to 14,907,407 ADSs and gross proceeds to approximately $201.3 million. The financing follows the August 10 Phase 2 SANRECO trial win in polycythemia vera with divesiran (first-in-class TMPRSS6-targeting siRNA that increases hepcidin production to restrict iron availability to bone marrow) achieving an 88% response rate versus 19% on placebo (P<0.0001, 69% placebo-adjusted response rate) in 48 phlebotomy-dependent patients over 36 weeks. Use of proceeds: advance divesiran into Phase 3 (planned initiation H1 2027 evaluating Q12W dosing versus placebo) plus broader pipeline progression including hepatic-target GalNAc-conjugated siRNA portfolio across TMPRSS6, complement component 3 (SLN-124/SLN-501), and other liver-targeted RNAi candidates. Divesiran has FDA Fast Track and Orphan Drug designations for polycythemia vera.